Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
Ocular Therapeutix, Inc. has a new large shareholder disclosure from Deep Track Capital and affiliates. As of December 31, 2025, they report beneficial ownership of 9,234,132 shares of common stock, representing 4.31% of the company.
The position includes 1,163,718 pre-funded warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” cap, meaning exercises cannot push the holder’s beneficial ownership above 9.99% of shares outstanding after exercise. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
Ocular Therapeutix details its strategy as an integrated biopharmaceutical company focused on retinal and other ophthalmic diseases using its ELUTYX hydrogel drug-delivery platform.
The lead asset AXPAXLI (OTX-TKI) is in Phase 3 registrational programs for wet age-related macular degeneration and diabetic retinal disease, targeting long-acting intravitreal therapy with 6–12 month dosing and potential NDA submission based primarily on the SOL-1 trial. The HELIOS program extends AXPAXLI into diabetic retinopathy using a novel ordinal DRSS endpoint.
Commercially, Ocular markets DEXTENZA, an FDA-approved dexamethasone intracanalicular insert for post-surgical ocular inflammation and pain and for ocular itching from allergic conjunctivitis, including pediatric use. The company is also evaluating next steps for glaucoma candidate OTX-TIC after completing Phase 2, and leverages partnerships with AffaMed in selected Asian markets.
Ocular Therapeutix, Inc. reported that it has released its financial results for the quarter and year ended December 31, 2025. These results were announced in a press release dated February 5, 2026.
The company furnished the full text of this earnings press release as Exhibit 99.1. This information is provided under a disclosure rule for earnings results and is designated as “furnished,” meaning it is not treated as formally “filed” under certain securities law liability provisions or automatically incorporated into other securities filings unless specifically referenced.
Ocular Therapeutix Chief Operating Officer Donald Notman reported two small sales of company common stock that were automatically executed to cover taxes on vested equity awards. On February 2, 2026, he sold 5,455 shares at a weighted average price of $9.14, tied to restricted stock units that vested January 30, 2026. On February 4, 2026, he sold 6,035 shares at a weighted average price of $8.54, related to restricted stock units that vested February 3, 2026. Both transactions were carried out under a durable automatic sales instruction letter dated May 13, 2022, and are described as non-discretionary sell-to-cover trades for tax withholding. After these transactions, Notman directly beneficially owned 377,802 shares of Ocular Therapeutix common stock.
Form 144 shows that Steve Meyers has filed a notice of intent to sell 4,408 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate aggregate market value of $37,636.39. The issuer has 213,047,472 shares outstanding.
The shares to be sold come from restricted stock vesting under a registered plan on 02/03/2026, acquired directly from the issuer. In the prior three months, Meyers sold 3,052 common shares for $27,903.83. The filer represents they know no undisclosed material adverse information.
Ocular Therapeutix shareholder Donald D Notman Jr has filed a Form 144 notice to sell up to 6,035 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ around February 4, 2026. These 6,035 shares were acquired on February 3, 2026 through restricted stock vesting under a registered plan. The notice states that there were 213,047,472 common shares outstanding. The filing also reports that Notman previously sold 5,455 common shares on February 2, 2026 for gross proceeds of $49,872.88.
An affiliate of OCUL has filed a Rule 144 notice to sell 5,455 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares have an indicated aggregate market value of $49,872.88 and were acquired on 01/30/2026 via restricted stock vesting under a registered plan. Common shares outstanding were 213,047,472 as of the filing, providing context for the planned sale size.
A shareholder of OCUL filed a notice of proposed sale under Rule 144 for 3,052 shares of common stock, with an aggregate market value of $27,903.83. The shares were acquired on 01/30/2026 through restricted stock vesting under a registered plan.
The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 02/02/2026. OCUL had 213,047,472 shares of common stock outstanding at the time referenced.
Ocular Therapeutix’s Global Chief Commercial Officer, David Wayne Robinson, reported new equity awards. On January 21, 2026, he received 136,000 restricted stock units (RSUs) of common stock at a price of $0. Each RSU represents one share of common stock and will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 416,000 shares of common stock at an exercise price of $11.42 per share. This option vests over four years: 25% of the underlying shares vest on the one-year anniversary of his first date of employment, and the balance vests in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 136,000 shares of common stock and 416,000 stock options.
Ocular Therapeutix, Inc. officer David Wayne Robinson, who serves as Global Chief Commercial Officer, filed an initial ownership report on Form 3. The filing states that he currently has no securities beneficially owned in Ocular Therapeutix, meaning he reports no direct or indirect holdings of the company’s stock or derivative securities at this time.